drugset / Trial / NCT07236788

Study on Supplement of Intravenous Ferric Derisomaltose to Prevent Anemia and Improve the Quality of Life in Obese Patients With Iron Deficiency.

NCT07236788

Recruiting 200 enrolled China-Japan Friendship Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

This study aimed to explore the effects of preoperative intravenous isomaltose iron supplementation versus placebo on postoperative Hb improvement, prevention of postoperative anemia, and improvement in quality of life in patients undergoing bariatric surgery.

Timeline

Start
2025-03-01
Primary completion
2026-12-30
Completion
2027-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Iron isomaltoside 1000 Unknown 20 mg/kg Intravenous
Subject Iron isomaltoside 1000 Unknown 500 mg Intravenous
Subject Iron isomaltoside 1000 Unknown 1000 mg Intravenous
Subject Iron isomaltoside 1000 Unknown 1500 mg Intravenous
Subject Iron isomaltoside 1000 Unknown 2000 mg Intravenous